BMY Quote, Trading Chart, Bristol-Myers Squibb Company
$65.94 Last:
-1.33% Change Percent:
$66.75 Open:
$65.94 Previous Close:
$66.79 High:
$65.71 Low:
9,457,373 Volume:
06/22/2021 04:43:24 am Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
BMY Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-06-22 | 66.75 | 65.94 | 66.79 | 65.71 | 9,457,373 |
| 2021-06-21 | 66.61 | 66.83 | 67.16 | 66.48 | 10,191,025 |
| 2021-06-18 | 66.4 | 66.47 | 66.73 | 65.78 | 15,036,750 |
| 2021-06-17 | 67.03 | 66.77 | 67.17 | 66.23 | 8,830,146 |
| 2021-06-16 | 67.42 | 66.92 | 67.86 | 66.8379 | 10,772,018 |
| 2021-06-15 | 67.5 | 67.42 | 67.5699 | 66.916 | 6,235,239 |
| 2021-06-14 | 67.32 | 67.29 | 67.45 | 66.65 | 5,424,418 |
| 2021-06-11 | 67.89 | 67.34 | 67.94 | 66.78 | 9,539,746 |
| 2021-06-10 | 65.55 | 67.39 | 67.7 | 65.42 | 14,988,043 |
| 2021-06-09 | 64.02 | 65.4 | 65.55 | 63.92 | 13,690,182 |
| 2021-06-08 | 64.81 | 63.7 | 64.89 | 63.22 | 14,416,239 |
| 2021-06-07 | 65.03 | 64.77 | 65.41 | 64.73 | 7,965,500 |
| 2021-06-04 | 64.98 | 64.94 | 65.23 | 64.86 | 8,014,355 |
| 2021-06-03 | 64.47 | 64.8 | 65.085 | 64.285 | 7,804,304 |
| 2021-06-02 | 65.24 | 64.69 | 65.42 | 64.535 | 7,496,840 |
| 2021-06-01 | 66.4 | 65.1 | 66.4 | 65.03 | 8,532,344 |
| 2021-05-31 | 65.66 | 65.72 | 66.21 | 65.6 | 6,356,983 |
| 2021-05-28 | 65.66 | 65.72 | 66.21 | 65.6 | 6,352,838 |
| 2021-05-27 | 66.3 | 65.71 | 66.65 | 65.58 | 12,139,864 |
| 2021-05-26 | 66.72 | 66.13 | 66.8 | 65.99 | 7,643,878 |
Bristol-Myers Squibb Company Company Name:
BMY Stock Symbol:
NYSE Market:
News, Short Squeeze, Breakout and More Instantly...
-
Onureg is the first and only once-daily, frontline oral maintenance therapy in the European Union (EU) for patients with a broad range of acute myeloid leukemia (AML) subtypes In the pivotal QUAZAR ® AML-001 study, Onureg significantly improved overall survi...
-
Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC). MORAb-202 is Ei...
-
Bristol Myers Squibb (NYSE: BMY) recently picked up another U.S. Food and Drug Administration (FDA) approval for Zeposia in treating ulcerative colitis. In this Motley Fool Live video recorded on June 2 , Motley Fool contributors Keith Speights and Brian Orelli discuss ...